Luis Palomera
A5080697191- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Chemokine receptors and signaling
- Cancer Treatment and Pharmacology
- Chronic Lymphocytic Leukemia Research
- Peptidase Inhibition and Analysis
- Lymphoma Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Amyloidosis: Diagnosis, Treatment, Outcomes
- HIV/AIDS drug development and treatment
- Chronic Myeloid Leukemia Treatments
- Monoclonal and Polyclonal Antibodies Research
- vaccines and immunoinformatics approaches
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- PI3K/AKT/mTOR signaling in cancer
- Cancer therapeutics and mechanisms
- Acute Lymphoblastic Leukemia research
- Viral-associated cancers and disorders
- Immunotherapy and Immune Responses
- Glycosylation and Glycoproteins Research
- Brain Metastases and Treatment
- Glioma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Head and Neck Surgical Oncology
Hospital Clínico Universitario Lozano Blesa
2016-2025
Instituto de Investigación Sanitaria Aragón
2022-2024
Instituto de Investigación Biomédica de Salamanca
2024
Centro de Investigación Biomédica en Red de Cáncer
2024
Nantes Université
2019
Inserm
2019
Université d'Angers
2019
Centre National de la Recherche Scientifique
2019
Centre d'Investigation Clinique de Nantes
2019
Hebrew University of Jerusalem
2019
Purpose To perform a critical analysis on the impact of depth response in newly diagnosed multiple myeloma (MM). Patients and Methods Data were analyzed from 609 patients who enrolled GEM (Grupo Español de Mieloma) 2000 GEM2005MENOS65 studies for transplant-eligible MM GEM2010MAS65 clinical trial elderly with had minimal residual disease (MRD) assessments 9 months after study enrollment. Median follow-up series was 71 months. Results Achievement complete remission (CR) absence MRD negativity...
To investigate the impact of immunophenotypic response (IR) versus complete (CR) and CR plus normal serum free light chain (sFLC) ratio (stringent CR) in elderly patients with multiple myeloma (MM) treated novel agents. Patients Methods From a total 260 newly diagnosed MM included GEM05>65y trial, 102 achieving at least partial ≥ 70% reduction M-component after six planned induction cycles were simultaneously analyzed by immunofixation, sFLC, multiparameter flow cytometry (MFC)...
Assessing measurable residual disease (MRD) has become standard with many tumors, but the clinical meaning of MRD in multiple myeloma (MM) remains uncertain, particularly when assessed by next-generation flow (NGF) cytometry. Thus, we aimed to determine applicability and sensitivity MRD-negative criterion defined International Myeloma Working Group (IMWG).In PETHEMA/GEM2012MENOS65 trial, 458 patients newly diagnosed MM had longitudinal assessment after six induction cycles bortezomib,...
To analyze the prognostic impact of immunophenotyping in patients with multiple myeloma (MM).We have prospectively analyzed antigenic markers, assessed by multiparametric flow cytometry, a series 685 newly diagnosed MM that were uniformly treated according to GEM 2000 protocol.Our results show expression both CD19 and CD28 as well absence CD117 associated significantly shorter progression free-survival (PFS) overall survival (OS). Interestingly, correlated t(14;16) del(17p), while...
Here, we investigated for the first time frequency and number of circulating tumor plasma cells (CTPC) in peripheral blood (PB) newly diagnosed patients with localized systemic cell neoplasms (PCN) using next-generation flow cytometry (NGF) correlated our findings distinct diagnostic prognostic categories disease. Overall, 508 samples from 264 PCN patients, were studied. CTPC detected PB all active multiple myeloma (MM; 100%), smoldering MM (SMM) (100%), more than half (59%) monoclonal...
Abstract Monitoring of the monoclonal protein (M-protein) by electrophoresis and/or immunofixation (IFE) has long been used to assess treatment response in multiple myeloma (MM). However, with use highly effective therapies, M-protein becomes frequently undetectable, and more sensitive methods had be explored. We applied IFE mass spectrometry (EXENT&FLC-MS) serum samples from newly diagnosed MM patients enrolled PETHEMA/GEM2012MENOS65 obtained at baseline (n = 223), after induction 183),...
Early treatment of high-risk smoldering myeloma has been shown to delay progression multiple (MM). We conducted this trial with curative intention using a approach employed for newly diagnosed patients MM.
New treatment options offering enhanced activity in elderly, newly diagnosed patients with multiple myeloma are required. One strategy is to combine melphalan and prednisone novel agents. We previously reported an 89% response rate, including 32% complete responses 11% near responses, our phase 1/2 study of bortezomib plus (VMP) 60 a median age 75 years. Here, we report updated time-to-events data the impact poor prognosis factors on outcome.Updated analyses time biochemical progression...